Detalhe da pesquisa
1.
Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022.
Influenza Other Respir Viruses;
17(6): e13144, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37273461
2.
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery.
PNAS Nexus;
2(12): pgad403, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38077689